Neoadjuvant chemotherapy for early-stage colon cancer
Colorectal cancer (CRC) is the 3rd most commonly diagnosed tumour and the 2nd leading cause of cancer-related deaths worldwide, with colonic tumours accounting for about two thirds of all these cases (1). Approximately 80% of patients are diagnosed with early-stage disease (2). In this setting, surgical resection is the mainstay of treatment, with 5-year survival rates of approximately 99% for stage I, 80% for stage II, and 50% for stage III cancers (3,4).
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Alessandro Audisio, Roberta Fazio, Valentina Dapr à, Irene Assaf, Alain Hendlis, Francesco Sclafani Tags: Hot Topic Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Colon Cancer | Colorectal Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy